Physician profile
Waldemar Torres
NPI 1275528051
$1,363.37
in general payments reported to CMS, 2019-2025
12 companies · $75.60 in 2025
The $75.60 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.24 · 2020: $61.28 · 2021: $493 · 2022: $116 · 2023: $274 · 2024: $302 · 2025: $75.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $395.86 | 2019-2025 | Eylea Hd |
| Alimera Sciences, INC. | $257.20 | 2020-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $144.96 | 2021-2023 | Eylea |
| Abbvie INC. | $143.80 | 2022-2025 | Ozurdex |
| Genentech, INC. | $124.96 | 2023 | Vabysmo |
| Harrow Eye, LLC | $97.40 | 2024 | Iheezo |
| Coherus Oncology, INC. | $81.20 | 2023-2024 | |
| Astellas Pharma US INC | $38.74 | 2024-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $22.04 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.23 | 2022 | |
| Biogen, INC. | $20.80 | 2023 | |
| Genentech USA, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldemar Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.